EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Transitional care services are cost-effective for older patients with chronic obstructive pulmonary disease in Korea

Yu Seong Hwang, Deog Kyeom Kim, Jung-Kyu Lee, Eun Young Heo, Hyun Woo Lee, Su Kyoung Kim, Yukyung Park, Woo Jin Kim, Seon Sook Han, Yeon Jeong Heo, Da Hye Moon, Oh Beom Kwon, Myung Goo Lee, Ji Young Hong, Chang Youl Lee, Heui Sug Jo

International Journal for Quality in Health Care · 2026-10-05 · 38 (4)

DOI: 10.1093/intqhc/mzag136 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Transitional care services (TCS) may reduce post-discharge readmissions and improve disease management in patients with chronic obstructive pulmonary disease (COPD). This study evaluated the cost-effectiveness of TCS using state-specific relative risks (RRs) derived from a randomized controlled trial (RCT). Methods Between September 2022 and September 2024, 417 patients with COPD discharged from three university hospitals in South Korea were assigned to TCS (n = 210) or usual care (n = 207). State-specific RRs were derived from 3-month RCT outcomes and incorporated into a Markov model with 3-month cycles and a 10-year time horizon. Costs and quality-adjusted life-years (QALYs) were estimated for patients in their 60 s, 70 s, and 80 s. Deterministic sensitivity analysis (DSA) and probabilistic sensitivity analysis (PSA) were performed to assess parameter uncertainty. Results In the base-case analysis, TCS increased costs by USD 2,128.91 and USD 1,133.41 per patient in the 60 s and 70 s cohorts, respectively, but reduced costs by USD 58.01 in the 80 s cohort. Incremental QALYs were 0.155, 0.195, and 0.271, respectively. The corresponding incremental cost-utility ratios were USD 13,709.60/QALY and USD 5,816.85/QALY in the 60 s and 70 s cohorts, while TCS was dominant in the 80 s cohort. DSA identified the RR of respiratory-disease readmission as the largest driver of uncertainty, followed by the RR of COPD readmission; the RR of other-disease readmission and TCS intervention cost were also influential. At a willingness-to-pay threshold of USD 23,050/QALY, the probabilities that TCS was cost-effective were 55.7%, 67.9%, and 82.7% for the 60 s, 70 s, and 80 s cohorts, respectively. Conclusions This study evaluated the cost-effectiveness of TCS for patients with COPD using state-specific RRs derived from an RCT. TCS was cost-effective across all age cohorts, with more favourable economic outcomes observed in older patients and dominance in the 80 s cohort. These findings support the implementation of TCS for patients with COPD, while further research is needed to confirm its long-term clinical and economic benefits.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →